Actuate Therapeutics announces EMA granted OMPD to elraglusib

Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to elraglusib, a novel GSK-3beta inhibitor, for the treatment of pancreatic ductal adenocarcinoma, PDAC. “With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s potential to address a critical need for people living with this aggressive disease with a notably poor prognosis,” said Daniel Schmitt, President & Chief Executive Officer of Actuate.